SERO Group is excited to announce the arrival of Aaron Wild, MD. Dr. Wild graduated from Yale University with his baccalaureate in Molecular Biophysics & Biochemistry in 2008 and from Johns Hopkins University School of Medicine with his MD degree in 2014. He completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center in New York, where he served as Chief Resident. He has expertise in treating all types of cancer with a special interest in gastrointestinal malignancies (pancreatic, liver, and rectal cancers), tumors involving the brain and spine, lung cancer, and prostate cancer.
Dr. Wild has participated in phase I, II, and III clinical trials as well as in translational laboratory based research. He has published more than 30 manuscripts in scientific and medical journals, including the Journal of Clinical Oncology, Nature Communications, Cancer, the Journal of the National Comprehensive Cancer Network, the International Journal of Radiation Oncology/Biology/Physics, Radiotherapy & Oncology, and Molecular Cancer Research. His work has been presented at national and international clinical and scientific meetings on more than 50 occasions.
He has experience in proton therapy, photon, electron, and brachytherapy based radiation treatment, including stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS). His mission as a radiation oncologist is to bring cutting edge cancer care of the highest quality to his patients in a way that best integrates with their individual goals and personal values while getting to know them and their families.
Outside of the office, he enjoys reading, the outdoors, sailing, skiing, sports, participating in his church, and spending time with his family and two dogs.
Dr. Wild started seeing patients on July 22, 2019 and will be practicing at various SERO departments.
Welcome, Dr. Wild!